english.prescrire.org > Spotlight > Archives : 2024 > Short-term interruption of treatment with a xaban or dabigatran: sometimes fatal thrombosis

Spotlight: Archives

Every month, the subjects in Prescrire’s Spotlight.

2024 : 1 | 30

Short-term interruption of treatment with a xaban or dabigatran: sometimes fatal thrombosis

 Adverse Effects   A study based on a South Korean health insurance database, including 11 000 patients with atrial fibrillation who were treated with a xaban-type oral anticoagulant or dabigatran and followed up for one year, showed that treatment interruption, even for one day, was associated with a 2-fold increase in the risk of premature death and a 10-fold increase in the risk of stroke, transient ischaemic attack or systemic embolism.
Full article available for download by subscribers

©Prescrire 1 October 2024

Source: "Short-term interruption of treatment with a xaban or dabigatran: sometimes fatal thrombosis" Prescrire Int 2024; 33 (263): 244. Subscribers only.

Enjoy full access to Prescrire International, and support independent information

 
Share
Share on Facebook Share on Twitter
 
See also:

"Apixaban, edoxaban,
rivaroxaban: situations
with a high risk of bleeding
or thrombosis"
Prescrire Int 2020;